Picture [LSUS] – The Business Web Portal 650x65px
Document › Details

Lytix Biopharma AS. (8/22/17). "Press Release: Norwegian Cancer Society Invests in Lytix Biopharma AS".

Organisations Organisation Lytix Biopharma AS
  Organisation 2 Norwegian Cancer Society
Products Product LTX-315 (Lytix Biopharma)
  Product 2 oncology
Index term Index term Lytix Biopharma–SEVERAL: investment, 201704 private placement NOK60m incl NOK6m from Norwegian Cancer Society
Person Person Wickholm, Håkan (Lytix Biopharma AS 201603– CEO)

Lytix Biopharma is pleased to announce that the Norwegian Cancer Society has invested 6 million NOK in the Company as part of the prior private placement of 60 million NOK.

”We are proud that this competent and important institution has invested in Lytix. This as a further confirmation that our drug development within immune-oncology is on the right track, and we greatly appreciate the value of having the Norwegian Cancer Society in place as a significant investor”, says Håkan Wickholm, CEO of Lytix Biopharma.

“We have followed Lytix Biopharma closely over some years. Their technology within oncolytic peptides has been evaluated thoroughly. LTX-315 is a very interesting drug candidate and we found the time right to invest in Lytix Biopharma. We hope that the future development can bring clinical benefits for our cancer patients”, says Anne Lise Ryel, Secretary General of the Norwegian Cancer Society.

Read related article in Dagens Medisin (only in Norwegian)

Record changed: 2017-08-30


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Lytix Biopharma AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 650x65px

» top